Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab + FOLFOX6 vs Cetuximab + FOLFIRI in mCRC (CECOG)
NCT00286130Phase 2Completed
- Sponsor
- Central European Cooperative Oncology Group
- Start
- Jul 2005
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 2, randomised, open-label trial of cetuximab in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Central European Cooperative Oncology Group. Primary endpoint: Progression-Free Survival Rate at 9 months. Started Jul 2005; status: completed.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00286130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00286130.